Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
BioMarin promotes Brian Mueller to executive VP, CFO » 16:21
06/29/20
06/29
16:21
06/29/20
16:21
BMRN

BioMarin

$122.21 /

-1.85 (-1.49%)

BioMarin Pharmaceutical…

BioMarin Pharmaceutical announced the promotions of Brian Mueller to executive VP, CFO and of Andrea Acosta to Group VP, Chief Accounting Officer. Mueller had been serving as senior VP, Acting CFO since February this year.

ShowHide Related Items >><<
BMRN BioMarin
$122.21 /

-1.85 (-1.49%)

BMRN BioMarin
$122.21 /

-1.85 (-1.49%)

06/19/20 Barclays
Barclays upgrades Swedish Orphan to Equal Weight on favorable trends
06/18/20 SunTrust
BioMarin price target raised to $143 from $109 at SunTrust
06/18/20 Oppenheimer
BioMarin price target raised to $95 from $88 at Oppenheimer
06/17/20 RBC Capital
RBC Capital says buy BioMarin on the dip after presenting Roctavian data
BMRN BioMarin
$122.21 /

-1.85 (-1.49%)

BMRN BioMarin
$122.21 /

-1.85 (-1.49%)

BMRN BioMarin
$122.21 /

-1.85 (-1.49%)

Hot Stocks
BioMarin names Brian Mueller as new CFO » 16:17
06/29/20
06/29
16:17
06/29/20
16:17
BMRN

BioMarin

$122.21 /

-1.85 (-1.49%)

BioMarin announced the…

BioMarin announced the promotions of Brian Mueller to Executive Vice President, CFO and of Andrea Acosta to Group Vice President, Chief Accounting Officer. Mr. Mueller had been serving as Senior Vice President, Acting CFO since February this year.

ShowHide Related Items >><<
BMRN BioMarin
$122.21 /

-1.85 (-1.49%)

BMRN BioMarin
$122.21 /

-1.85 (-1.49%)

06/19/20 Barclays
Barclays upgrades Swedish Orphan to Equal Weight on favorable trends
06/18/20 SunTrust
BioMarin price target raised to $143 from $109 at SunTrust
06/18/20 Oppenheimer
BioMarin price target raised to $95 from $88 at Oppenheimer
06/17/20 RBC Capital
RBC Capital says buy BioMarin on the dip after presenting Roctavian data
BMRN BioMarin
$122.21 /

-1.85 (-1.49%)

BMRN BioMarin
$122.21 /

-1.85 (-1.49%)

BMRN BioMarin
$122.21 /

-1.85 (-1.49%)

Over a week ago
Upgrade
Barclays upgrades Swedish Orphan to Equal Weight on favorable trends » 06:17
06/19/20
06/19
06:17
06/19/20
06:17
BIOVF

Swedish Orphan Biovitrum

$0.00 /

+ (+0.00%)

, BMRN

BioMarin

$113.83 /

+2.34 (+2.10%)

Barclays analyst Emmanuel…

Barclays analyst Emmanuel Papadakis upgraded Swedish Orphan Biovitrum (BIOVF) to Equal Weight from Underweight with a price target of SEK 205, up from SEK 170. Recent trends have been largely favorable, with a strong start to the year for Synagis, a sustained COVID-19 "tailwind" for Kineret demand and a deferral of haemophilia risks in Europe with the delay to Hemlibra's rollout and delay in BioMarin's (BMRN) EU gene therapy review to early 2021, Papadakis tells investors in a research note. The analyst now sees a "far more evenly balanced" risk/reward in the short term for Swedish Orphan Biovitrum shares.

ShowHide Related Items >><<
BMRN BioMarin
$113.83 /

+2.34 (+2.10%)

BIOVF Swedish Orphan Biovitrum
$0.00 /

+ (+0.00%)

06/19/20 Barclays
Swedish Orphan upgraded to Equal Weight from Underweight at Barclays
07/18/19 Deutsche Bank
Swedish Orphan Biovitrum downgraded to Hold from Buy at Deutsche Bank
BMRN BioMarin
$113.83 /

+2.34 (+2.10%)

06/18/20 SunTrust
BioMarin price target raised to $143 from $109 at SunTrust
06/18/20 Oppenheimer
BioMarin price target raised to $95 from $88 at Oppenheimer
06/17/20 RBC Capital
RBC Capital says buy BioMarin on the dip after presenting Roctavian data
06/17/20 Piper Sandler
Piper sees BioMarin having 'revolutionary long-term option' for Hemophilia A
BMRN BioMarin
$113.83 /

+2.34 (+2.10%)

BMRN BioMarin
$113.83 /

+2.34 (+2.10%)

BMRN BioMarin
$113.83 /

+2.34 (+2.10%)

Conference/Events
JPMorgan large cap biotech analyst to hold an analyst/industry conference call » 11:55
06/18/20
06/18
11:55
06/18/20
11:55
BMRN

BioMarin

$114.00 /

+2.51 (+2.25%)

Large Cap Biotech Analyst…

Large Cap Biotech Analyst Kasimov, along with Dr. Joel Brill, Chief Medical Officer at Predictive Health, assesses the payor landscape for BioMarin's Roctavian on an Analyst/Industry conference call to be held on June 18 at 12:30 pm.

ShowHide Related Items >><<
BMRN BioMarin
$114.00 /

+2.51 (+2.25%)

BMRN BioMarin
$114.00 /

+2.51 (+2.25%)

06/18/20 SunTrust
BioMarin price target raised to $143 from $109 at SunTrust
06/18/20 Oppenheimer
BioMarin price target raised to $95 from $88 at Oppenheimer
06/17/20 RBC Capital
RBC Capital says buy BioMarin on the dip after presenting Roctavian data
06/17/20 Piper Sandler
Piper sees BioMarin having 'revolutionary long-term option' for Hemophilia A
BMRN BioMarin
$114.00 /

+2.51 (+2.25%)

BMRN BioMarin
$114.00 /

+2.51 (+2.25%)

BMRN BioMarin
$114.00 /

+2.51 (+2.25%)

Conference/Events
JPMorgan large cap biotech analyst to hold an analyst/industry conference call » 09:55
06/18/20
06/18
09:55
06/18/20
09:55
BMRN

BioMarin

$114.40 /

+2.91 (+2.61%)

Large Cap Biotech Analyst…

Large Cap Biotech Analyst Kasimov, along with Dr. Joel Brill, Chief Medical Officer at Predictive Health, assesses the payor landscape for BioMarin's Roctavian on an Analyst/Industry conference call to be held on June 18 at 12:30 pm.

ShowHide Related Items >><<
BMRN BioMarin
$114.40 /

+2.91 (+2.61%)

BMRN BioMarin
$114.40 /

+2.91 (+2.61%)

06/18/20 SunTrust
BioMarin price target raised to $143 from $109 at SunTrust
06/18/20 Oppenheimer
BioMarin price target raised to $95 from $88 at Oppenheimer
06/17/20 RBC Capital
RBC Capital says buy BioMarin on the dip after presenting Roctavian data
06/17/20 Piper Sandler
Piper sees BioMarin having 'revolutionary long-term option' for Hemophilia A
BMRN BioMarin
$114.40 /

+2.91 (+2.61%)

BMRN BioMarin
$114.40 /

+2.91 (+2.61%)

BMRN BioMarin
$114.40 /

+2.91 (+2.61%)

Recommendations
BioMarin price target raised to $143 from $109 at SunTrust » 08:57
06/18/20
06/18
08:57
06/18/20
08:57
BMRN

BioMarin

$111.49 /

+5.21 (+4.90%)

SunTrust analyst Robyn…

SunTrust analyst Robyn Karnauskas raised the firm's price target on BioMarin to $143 from $109 and keeps a Buy rating on the shares after the company presented its Roctavian data. The analyst is modeling the course price at $2M vs. $1M prior and expects its 4-year annualized bleed rate durability to lead to "favorable payer discussion". Karnauskas adds that the "strongly positive" feedback from opinion leaders suggests a "transformational" nature of the Roctavian therapy.

ShowHide Related Items >><<
BMRN BioMarin
$111.49 /

+5.21 (+4.90%)

BMRN BioMarin
$111.49 /

+5.21 (+4.90%)

06/18/20 Oppenheimer
BioMarin price target raised to $95 from $88 at Oppenheimer
06/17/20 RBC Capital
RBC Capital says buy BioMarin on the dip after presenting Roctavian data
06/17/20 Piper Sandler
Piper sees BioMarin having 'revolutionary long-term option' for Hemophilia A
06/10/20 BofA
BioMarin price target raised to $130 from $120 at BofA
BMRN BioMarin
$111.49 /

+5.21 (+4.90%)

BMRN BioMarin
$111.49 /

+5.21 (+4.90%)

BMRN BioMarin
$111.49 /

+5.21 (+4.90%)

Recommendations
BioMarin price target raised to $95 from $88 at Oppenheimer » 07:28
06/18/20
06/18
07:28
06/18/20
07:28
BMRN

BioMarin

$111.49 /

+5.21 (+4.90%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell raised the firm's price target on BioMarin to $95 from $88 and keeps a Perform rating on the shares. The analyst notes that incremental Phase 2 Roctavian data has been presented virtually at the World Federation of Hemophilia come essentially in-line. Respective three- and four-year experience with 4e13 and 6e13 vg/kg doses demonstrate maintenance of clinical benefit, while FVIII activity continues to decline, albeit at a more gradual rate, he highlights. Gershell continues to anticipate accelerated approval on/around the 8/21 PDUFA date, and believes the demonstration of meaningful clinical benefit out to at least four years will support robust pricing. Nonetheless, he keeps a tempered view on commercial uptake in light of physician commentary.

ShowHide Related Items >><<
BMRN BioMarin
$111.49 /

+5.21 (+4.90%)

BMRN BioMarin
$111.49 /

+5.21 (+4.90%)

06/17/20 RBC Capital
RBC Capital says buy BioMarin on the dip after presenting Roctavian data
06/17/20 Piper Sandler
Piper sees BioMarin having 'revolutionary long-term option' for Hemophilia A
06/10/20 BofA
BioMarin price target raised to $130 from $120 at BofA
06/05/20 Barclays
BioMarin price target raised to $125 from $105 at Barclays
BMRN BioMarin
$111.49 /

+5.21 (+4.90%)

BMRN BioMarin
$111.49 /

+5.21 (+4.90%)

BMRN BioMarin
$111.49 /

+5.21 (+4.90%)

Recommendations
RBC Capital says buy BioMarin on the dip after presenting Roctavian data » 11:31
06/17/20
06/17
11:31
06/17/20
11:31
BMRN

BioMarin

$109.27 /

+2.99 (+2.81%)

After BioMarin presented…

After BioMarin presented detailed data from the Phase 1/2 study of Roctavian in hemophilia A at the WFH 2020 Virtual Congress, RBC Capital analyst Kennen Mackay says he would buy the stock on the dip. The analyst continues to see Roctavian's clean safety profile with sustained durable increases in FVIII activity and prevention of bleed recurrence in the vast majority of patients suggestive of a practice changing drug profile that will be highly enticing to patients. The analyst, who models risk-unadjusted respective 2020/2021 Roctavian revenues of $31M/$263M, made no change to his OUtperform rating.

ShowHide Related Items >><<
BMRN BioMarin
$109.27 /

+2.99 (+2.81%)

BMRN BioMarin
$109.27 /

+2.99 (+2.81%)

06/17/20 Piper Sandler
Piper sees BioMarin having 'revolutionary long-term option' for Hemophilia A
06/10/20 BofA
BioMarin price target raised to $130 from $120 at BofA
06/05/20 Barclays
BioMarin price target raised to $125 from $105 at Barclays
05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
BMRN BioMarin
$109.27 /

+2.99 (+2.81%)

BMRN BioMarin
$109.27 /

+2.99 (+2.81%)

BMRN BioMarin
$109.27 /

+2.99 (+2.81%)

Recommendations
Piper sees BioMarin having 'revolutionary long-term option' for Hemophilia A » 10:45
06/17/20
06/17
10:45
06/17/20
10:45
BMRN

BioMarin

$109.08 /

+2.8 (+2.63%)

After written commentary…

After written commentary sparked concerns over continuing declines in Factor VIII levels at 4 years in Biomarin's Phase 1/2 study, the company reported mean four year F8 levels of 24.2 IU/year, which Piper Sandler analyst Christopher Raymond said is in line with Biomarin's durability modeling. The analyst, who contends that BioMarin "does not just have a drug here, it has a revolutionary long-term option for Hemophilia A," keeps an Overweight rating on the shares following the late-breaking abstract presentation at the World Federation of Hemophilia.

ShowHide Related Items >><<
BMRN BioMarin
$109.08 /

+2.8 (+2.63%)

BMRN BioMarin
$109.08 /

+2.8 (+2.63%)

06/10/20 BofA
BioMarin price target raised to $130 from $120 at BofA
06/05/20 Barclays
BioMarin price target raised to $125 from $105 at Barclays
05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
05/26/20 RBC Capital
BioMarin among Sanofi's most intriguing potential targets, says RBC Capital
BMRN BioMarin
$109.08 /

+2.8 (+2.63%)

BMRN BioMarin
$109.08 /

+2.8 (+2.63%)

BMRN BioMarin
$109.08 /

+2.8 (+2.63%)

Hot Stocks
BioMarin provides updated data from Phase 1/2 study of hemophilia A candidate » 09:26
06/17/20
06/17
09:26
06/17/20
09:26
BMRN

BioMarin

$106.28 /

+0.49 (+0.46%)

BioMarin announced…

BioMarin announced additional data from its previously reported four-year update of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia A. The results were presented at the World Federation of Hemophilia Virtual Summit. In the six study participants who were previously on Factor VIII prophylaxis in the 6e13 vg/kg cohort, the data showed substantial and sustained reductions in bleeding that required Factor VIII infusions. During the four years following treatment with valoctocogene roxaparvovec, the cumulative mean Annualized Bleed Rate was 0.8, a 95% reduction from baseline. In the fourth year, the mean ABR was 1.3 and the median was zero. 86% or six out of seven were bleed-free in the fourth year. In the six study participants in the 4e13 vg/kg cohort, the data showed substantial and sustained reductions in bleeding requiring Factor VIII infusions following treatment with valoctocogene roxaparvovec. The safety profile of valoctocogene roxaparvovec remains consistent with previously reported data with no delayed-onset, treatment-related events. BioMarin has five clinical studies underway in its comprehensive gene therapy program for the treatment of severe hemophilia A. The FDA is reviewing the biologics license application, under Priority Review, for valoctocogene roxaparvovec with a PDUFA action date of August 21. The FDA also granted valoctocogene roxaparvovec Breakthrough Therapy designation. The European Medicines Agency validated the company's Marketing Authorization Application for valoctocogene roxaparvovec, in review under accelerated assessment since January. The company expects an opinion from the Committee for Medicinal Products for Human Use in late 2020/early 2021. BioMarin's valoctocogene roxaparvovec has also received orphan drug designation from the FDA and EMA for the treatment of severe hemophilia A.

ShowHide Related Items >><<
BMRN BioMarin
$106.28 /

+0.49 (+0.46%)

BMRN BioMarin
$106.28 /

+0.49 (+0.46%)

06/10/20 BofA
BioMarin price target raised to $130 from $120 at BofA
06/05/20 Barclays
BioMarin price target raised to $125 from $105 at Barclays
05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
05/26/20 RBC Capital
BioMarin among Sanofi's most intriguing potential targets, says RBC Capital
BMRN BioMarin
$106.28 /

+0.49 (+0.46%)

BMRN BioMarin
$106.28 /

+0.49 (+0.46%)

BMRN BioMarin
$106.28 /

+0.49 (+0.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.